Jun 07, 2023 / 12:00PM GMT
Roger Song - Jefferies LLC - Analyst
All right, welcome, everyone, for the day one 2023 Jefferies Healthcare Conference. Our first company is Prelude Therapeutics. And with us today is CEO, Kris Vaddi; and President and the CMO, Jane Huang, welcome.
All right, maybe kick this off. What will be your updated one-minute elevator for those people already know Prelude or maybe kind of new to the story.
Kris Vaddi - Prelude Therapeutics Incorporated - CEO
Roger, thank you very much for the opportunity to participate in your conference. So Prelude is a precision oncology company with a deep and balanced portfolio of clinical stage molecules, a very powerful R&D engine, and an exceptional management team, leadership team with proven track record. And we are advancing our molecules in Phase 1 clinical trials with the ones in the clinic and the new molecules are about to enter clinic over the course of next 12 months or so.
So what sets us apart is really the first-in-class molecules as well as best-in-class potential molecules in our clinical
Prelude Therapeutics Inc at Jefferies Healthcare Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers